Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Cellebrite DI Ltd shares valued at $376,996 were purchased by LEEOR MOSHE BEN-PERETZ on Mar 25 ’25. At $20.36 per share, LEEOR MOSHE BEN-PERETZ acquired 18,512 shares.
Also, LEEOR MOSHE BEN-PERETZ purchased 15,680 shares, netting a total of over 296,920 in proceeds.
Before that, YOSEF CARMIL had added 200,000 shares to its account. In a trade valued at $3,650,000, the Officer bought Cellebrite DI Ltd shares for $18.25 each.
As published in a research note from Needham on March 28, 2024, Cellebrite DI Ltd [CLBT] has been retained to a Buy and the price target has been revised to $13.50. Analysts at William Blair upgraded the stock from ‘”a Mkt perform”‘ to ‘”an Outperform”‘ outlook in a report released in mid March. As of February 16, 2024, BofA Securities has increased its “Neutral” rating to a “Buy” for CLBT. Earlier on July 19, 2023, Craig Hallum initiated its rating. Their recommendation was “a Buy” for CLBT stock.
Analyzing CLBT Stock Performance
During the last five days, there has been a drop of approximately -1.45%. Over the course of the year, Cellebrite DI Ltd shares have dropped approximately -13.48%. Shares of the company reached a 52-week high of $26.30 on 02/06/25 and a 52-week low of $16.17 on 03/10/25. A 50-day SMA is recorded $19.07, while a 200-day SMA reached $18.48.
Support And Resistance Levels for Cellebrite DI Ltd (CLBT)
According to the 24-hour chart, there is a support level at 18.78, which, if violated, would cause prices to drop to 18.50. In the upper region, resistance lies at 19.46. The next price resistance is at 19.87. RSI (Relative Strength Index) is 50.80 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.11, which suggests the price will decrease in the coming days. Percent R is at 21.74%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
